Related Experiment Videos
Management of membranoproliferative glomerulonephritis: evidence-based recommendations
1Division of Nephrology, University of British Columbia, St. Paul's Hospital, Vancouver, Canada. alevin@stpaulshosp.bc.ca
Abstract:
Idiopathic membranoproliferative glomerulonephritis (MPGN) is one of the least common types of GN. This article critically evaluates the literature and generates evidence-based recommendations for the management of idiopathic MPGN. For all age groups, for idiopathic MPGN with normal renal function and asymptomatic nonnephrotic range proteinuria, no specific therapy is necessary (grades B and C). Close follow-up every three to four months, with specific attention to renal function, proteinuria, and blood pressure control, is recommended. In children with MPGN and nephrotic syndrome and/or impaired renal function, a trial of steroids is warranted (grade A). The best data suggest high-dose, alternate-day steroids for a period of 6 to 12 months (40 mg/m2 on alternate days). If no benefit is seen, discontinuation with close follow-up and attention to conservative treatment (that is, blood pressure control, use of agents to reduce proteinuria, and correction of metabolic abnormalities) is recommended. In adults with MPGN, impaired renal function, and/or nephrotic-range proteinuria, a trial of aspirin (325 mg daily), dipyridamole (75 to 100 mg tid), or a combination of the two for 12 months is reasonable (grade B). Again, if no benefits are seen, the treatment should be stopped. Attention to factors known to delay the progression of renal decline and close follow-up should be part of the treatment plan (grades B and C).
Insights
Idiopathic membranoproliferative glomerulonephritis (MPGN) management varies by patient age and kidney function. Children with MPGN and impaired kidney function may benefit from steroids, while adults may try aspirin and dipyridamole.
Area of Science:
- Nephrology
- Internal Medicine
- Glomerular Diseases
Background:
- Idiopathic membranoproliferative glomerulonephritis (MPGN) is a rare kidney disease.
- Evidence-based management guidelines for MPGN are lacking.
Purpose of the Study:
- To critically evaluate existing literature on idiopathic MPGN.
- To generate evidence-based recommendations for MPGN management across different age groups and clinical presentations.
Main Methods:
- Systematic literature review and evidence synthesis.
- Development of clinical recommendations based on evaluated data quality (grades A, B, C).
Main Results:
- No specific therapy is recommended for asymptomatic patients with normal renal function.
- Children with nephrotic syndrome or impaired renal function may benefit from a trial of high-dose, alternate-day steroids for 6-12 months.
- Adults with impaired renal function or nephrotic-range proteinuria may consider a 12-month trial of aspirin, dipyridamole, or combination therapy.
Conclusions:
- Management strategies for idiopathic MPGN should be tailored to patient age, renal function, and proteinuria levels.
- Conservative management, including blood pressure control and proteinuria reduction, is crucial for all patients.
- Close monitoring of renal function and proteinuria is essential for guiding treatment decisions and managing disease progression.